All In Biotech

Drug Trial Radar · NCT02775916

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Jun 1, 2016

Primary completion

May 17, 2017

Study completion May 17, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 18, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173 in patients with primary Sjögren's syndrome.

Conditions

  • Primary Sjögren's Syndrome

Interventions

  • CDZ173Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85Time frame: up to Day 85
  2. Change From Baseline in the EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI) After 12 Weeks of Treatment Day 85Time frame: Baseline and 12 weeks (Day 85)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Debrecen, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.